Skip to content
sellWeak cluster of 310b5-1 plan

Carl N Kraus sold $142k of AQST

Chief Medical Officer at Aquestive Therapeutics, Inc.. 20,272 shares at an average of $7.00, traded Oct 15, 2025, filed Oct 17, 2025.

Warning score
21
Value
$142k
20,272 shares
Holdings after
282,475
-7% from before
From 52-week low
+231%
low $2.22, close $7.34
From 52-week high
0%
high $7.34, as of Oct 15, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $142k at market
    +11
  • Share of holdings sold
    Sold 6.7% of holdings
    0
  • Cluster
    3 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

AQSTOct 9, 2026 · close 4.78
Since filing Oct 17, 2025: -32.5%SPY +18.4% · excess -50.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001214659-25-015047, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 15, 2025SOpen-market sale
Common Stock10b5-1
-20,272$7.00$142k282,475Oct 17, 2025

Related signals

Other insiders at Aquestive Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
23Weak
AQSTsell 210b5-1
Aquestive Therapeutics, Inc.
Daniel Barber
President and CEO
$120k
25,000 shares
-4%
0Weak
AQSTsell 210b5-1
Aquestive Therapeutics, Inc.
Sherry Korczynski
Chief Commercial Officer
$46k
8,750 shares
-4%
18Weak
AQSTsell 310b5-1
Aquestive Therapeutics, Inc.
Peter E. Boyd
See Remarks
$70k
10,000 shares
-4%
22Weak
AQSTsell 310b5-1
Aquestive Therapeutics, Inc.
Cassie Jung
Chief Operating Officer
$474k
67,575 shares
-22%
11Weak
AQSTsell 210b5-1
Aquestive Therapeutics, Inc.
Peter E. Boyd
See Remarks
$63k
10,000 shares
-3%
32Weak
AQSTsell 210b5-1
Aquestive Therapeutics, Inc.
Daniel Barber
President and CEO
$551k
91,343 shares
-9%
13Weak
AQSTsell 210b5-1
Aquestive Therapeutics, Inc.
Daniel Barber
President and CEO
$2,400
400 shares
-0%
19Weak
AQSTsell 310b5-1
Aquestive Therapeutics, Inc.
Peter E. Boyd
See Remarks
$80k
15,000 shares
-5%
12Weak
AQSTsell 210b5-1
Aquestive Therapeutics, Inc.
Cassie Jung
Chief Operating Officer
$311k
62,180 shares
-18%
40Moderate
AQSTsell
Aquestive Therapeutics, Inc.
Cassie Jung
Chief Operating Officer
$214
44 shares
-100%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Carl N Kraus sold $142k of AQST | InsiderTell